





Types of Drugs/Substances

Dr Urvisha Bhoora

MBBCh (Wits), FCFP (SA), MMed (Family Medicine) UP

09/05/2019


DRUGS DESCRIBED THROUGH THE MANY FACES OF JIM CARREY



FACEBOOK.COM/WEEDLAUGHS420



Overview

- Different classes of drugs
 - Cannabis
 - Opioids
 - Hallucinogens
- 

SUBSTANCES

STIMULANTS

- Speed up the CNS and create a feeling of alertness and ↑energy.
- Called “uppers” →ability to make you feel very awake. When the effects of a stimulant wear off, the user is typically left with feelings of sickness and a loss of energy.

Types of drugs include:

- ❖ Caffeine
- ❖ Cocaine
- ❖ Methamphetamines
- ❖ Amphetamines
- ❖ Methylphenidate (Ritalin)



METHYLPHENIDATE (MPH)/RITALIN

- ▶ Only schedule 6 stimulant available in SA for treatment of ADD/ADHD and narcolepsy.¹
- ▶ Used amongst students to strengthen academic performance by improving concentration and allowing one to study for long periods at a time.
- ▶ Adverse effects: loss of appetite, difficulty sleeping, dry mouth, irritability and depressed mood
- ▶ S Afr J Psychiat. 2016 → survey 818 undergraduate students in a South African university
 - 17.2% of students had used MPH in the past and only 2.3% had a diagnosis of ADD/ADHD²
- ▶ S Afr J Psychiat. 2017 → questionnaire 541 medical students in UFS from 1st-5th year
 - Different response rates from different years
 - Overall close to 10% used MPH, 30% had a diagnosis of ADD/ADHD¹

SUBSTANCES

DEPRESSANTS

- Slow down CNS activity
- Called “downers” → give feelings of relaxation
- Large amounts → feeling less pain, more relaxed and sleepy
- Moderate use → more likely to result in euphoria than depression

Types of drugs include:

- ❖ Barbiturates
- ❖ Benzodiazepines
- ❖ Flunitrazepam (Rohypnol, “date rape drug”)
- ❖ GHB (Gamma-hydroxybutyrate)
- ❖ Methaqualone (Mandrax, Buttons)
- ❖ Alcohol
- ❖ Tranquillisers



SUBSTANCES

INHALANTS

- Sniffed or huffed and give the user immediate results.
- When inhalants are taken, the body becomes hypoxic → sudden brain damage.
- Other effects include tachycardia, liver, lung and kidney problems, affected sense of smell, difficulty walking and confusion.

Types of drugs include:

- ❖ Glues
- ❖ Paint thinner
- ❖ Gasoline
- ❖ Laughing gas
- ❖ Aerosol sprays



SUBSTANCES

CANNABINOIDS

- Result in feelings of euphoria, cause confusion and memory problems, anxiety, tachycardia, as well as staggering and poor reaction time.
- Can produce hallucinations, esp with heavy use, or inexperienced users

Types of drugs include:

- Hashish
- Marijuana





SUBSTANCES

- Decriminalisation- removal of criminal sanctions for certain offenses (usually possession of small quantities of currently illegal drugs for personal use). Possession of drugs remains unlawful and a punishable offense (community service/fines) but no longer attracts a criminal record.
- Legalisation- removal of all types of penalty, criminal or administrative- for production, supply and possession
- Regulation- framework of rules that sets the parameters for the legal production, supply and possession of a potentially harmful substance. (Alcohol and Tobacco)
- UNODC ~4% of the global adult population have used cannabis in their life




SUBSTANCES


CANNABIS PLANT

- ▶ The plant genus *Cannabis* is commonly divided in two species: *Cannabis sativa* and *Cannabis indica*.
- ▶ Male, female or hermaphrodite plants
- ▶ The cannabis plant is comprised of several structures.
- ▶ Cannabis grows on long skinny stems with its large, iconic fan leaves extending out from areas called **nodes**.
- ▶ A **cola** → cluster of buds that grow tightly together.



CANNABIS PLANT CONT...

- The **pistil** contains the reproductive parts of a flower, and the hair-like strands of the pistil are called **stigmas**.
 - Stigmas serve to collect pollen from males.
 - A **bract** is what encapsulates the female's reproductive parts and are heavily covered in resin glands which produce the highest concentration of cannabinoids of all plant parts.
 - Enclosed by these bracts and imperceptible to the naked eye, the **calyx** refers to a translucent layer over the ovule at a flower's base.
 - **Trichomes** → clear bulbous globes secrete oils called terpenes as well as cannabinoids like THC (Tetrahydrocannabinol) and CBD (cannabidiol)
- 



CANNABINOIDS

PHYSIOLOGY/PHARMACOLOGY

- ▶ Endocannabinoids (eCBs) and their receptors are found throughout the human body: nervous system, internal organs, connective tissues, glands, and immune cells.
- ▶ The eCB system has a homeostatic role, characterized as “eat, sleep, relax, forget, and protect.”
- ▶ It is known that eCBs have a role in the pathology of many disorders while also serving a protective function in certain medical conditions.
- ▶ It has been proposed that migraine, fibromyalgia, irritable bowel syndrome, and related conditions represent clinical eCB deficiency syndromes.

CANNABINOIDS

PHYSIOLOGY/PHARMACOLOGY CONTINUED

- ▶ Cannabinoid receptor type 1 (CB1) is the most abundant G-protein-coupled receptor.
- ▶ It is expressed in the central nervous system with particularly dense expression in (ranked in order): the substantia nigra, globus pallidus, hippocampus, cerebral cortex, putamen, caudate, cerebellum, and amygdala
- ▶ CB1 is also expressed in non-neuronal cells, such as adipocytes and hepatocytes, connective and musculoskeletal tissues, and the gonads.
- ▶ CB2 is principally associated with cells governing immune function, although it may also be expressed in the central nervous system
- ▶ Δ^9 THC is known to be the major psychoactive component of cannabis mediated by activation of the CB1 receptors in the central nervous system
- ▶ Psychoactive and negative effects are related to concentrations of THC.



CANNABINOIDS

PHYSIOLOGY/PHARMACOLOGY CONTINUED

- Unlike THC, CBD elicits its pharmacological effects without exerting any significant intrinsic activity on CB1 and CB2 receptors.
- CBD appears to have the ability to counteract psychotic symptoms and cognitive impairment associated with cannabis use as well as with acute THC administration
- Several activities give CBD a high potential for therapeutic use, including antiepileptic, anxiolytic, anti-psychotic, anti-inflammatory, and neuroprotective effects.

CANNABINOIDS

MEDICINAL USE

- ▶ American Academy of Neurology (AAN) issued a Summary of Systematic Reviews for Clinicians → oral cannabis extract is effective for reducing patient-reported spasticity scores and central pain or painful spasms when used for MS
- ▶ Systematic Review and Meta-analysis 2016 →
 - Moderate-quality evidence to support the use of cannabinoids for the treatment of chronic pain and spasticity.
 - Low-quality evidence suggesting that cannabinoids were associated with improvements in nausea and vomiting due to chemotherapy, weight gain in HIV, sleep disorders, and Tourette syndrome



CANNABINOIDS

MEDICINAL USE

- Recently, 3 high quality placebo-controlled adjunctive therapy trials of a purified CBD product in patients with Dravet Syndrome and Lennox-Gastaut Syndrome → CBD superior to placebo in reducing the frequency of convulsive seizures in DS and frequency of drop-seizures in LGS
- In the US, 28 states allow comprehensive public medical marijuana and cannabis programs
- The most common conditions accepted by states that allow medicinal cannabis relate to relief of the symptoms of cancer, glaucoma, HIV/AIDS, and MS.

CANNABINOIDS

CHALLENGES

- ▶ Short-term use of cannabis has led to impaired short-term memory; impaired motor coordination; altered judgment; and paranoia or psychosis at high doses.
- ▶ Long- term/heavy use of cannabis, especially in individuals who begin using as adolescents →dependence; altered brain development; cognitive impairment; poor educational outcomes (e.g. dropping out of school); and diminished life satisfaction.
- ▶ Long-term/heavy use of cannabis associated with chronic bronchitis and an increased risk of chronic psychosis-related health disorders, including schizophrenia and variants of depression, in persons with a predisposition to such disorders

CANNABINOIDS

CHALLENGES

- ▶ Lancet Psychiatry (2019): Included patients aged 18–64 years who presented to psychiatric services across Europe and Brazil with first-episode psychosis. Between 1 May 2010 and 1 April 2015 obtained data from 901 patients with first-episode psychosis across 11 sites and 1237 population controls from those same sites
- Using Europe-wide and national data on the expected concentration of Δ^9 THC in the different types of cannabis →divided the types of cannabis used by participants into: low potency (THC <10%) and high potency (THC \geq 10%)
- Findings: Daily cannabis use was associated with increased odds of psychotic disorder compared with never users, **increasing to nearly five-times increased odds for daily use of high-potency types of cannabis.**




SYNTHETIC CANNABINOIDS (SC)

- Synthetic drugs contain a mixture of psychoactive compounds that mostly bind cannabinoid receptors with high potency.
- Replicate the effects of natural cannabis and Δ^9 THC but induce more severe adverse effects
- Chronic use of SC has been associated with serious psychiatric and medical conditions and even death
- Used recreationally, especially by young adults
- Compounds show differences in their selectivity, their potency and their function



SYNTHETIC CANNABINOIDS (SC)

- ▶ In general they are more potent and efficacious cannabinoid receptor agonists than THC
 - ▶ Mostly undetectable via a simple urine test
 - ▶ Major differences between the effect of cannabis and SC drugs, both in terms of spectrum and intensity of these effects
 - ▶ In USA there were 37,500 reported cases of seizures and 3,682 reported cases of poisonings related to SC use during 2014
- 

SUBSTANCES

OPIOIDS & MORPHINE DERIVATIVES

▶ Can cause feelings of euphoria, drowsiness, confusion, nausea, respiratory complications and relieve pain.

Types of drugs include:

- ❖ Codeine
- ❖ Fentanyl and fentanyl analogues
- ❖ Heroin
- ❖ Morphine
- ❖ Opium
- ❖ Oxycodone HCL
- ❖ Hydrocodone bitartrate




Heroin's effects on the body

Short-term effects of Heroin



Long-term effects of Heroin



SUBSTANCES

HALLUCINOGENS

- Different classes:
 - Psychedelics (serotonin 2A receptor (5-HT_{2A}R) agonists → lysergic acid diethylamide (**LSD**), psilocybin (**magic mushrooms**), and N,N-dimethyltryptamine (**DMT**), mescaline (cactus **Peyote** [Lophophora williamsii])
 - Entactogens → MDMA (ecstasy)
 - Dissociatives → Ketamine
 - Atypical hallucinogens → Ibogaine
- Induce temporary but profound alterations of consciousness, involving acute changes in somatic, perceptual, cognitive, and affective processes



LSD

- ▶ Acts primarily as a serotonergic agonist, but also shows action at dopaminergic and adrenergic receptor sites
- ▶ Subjective effects → can last up to 12 hours, with rapid tolerance developed after repeated administration, and no evidence of withdrawal
- ▶ Acutely increases plasma cortisol, prolactin, oxytocin, and adrenalin levels
- ▶ Effects of LSD last slightly longer than other psychedelics such as psilocybin and mescaline
- ▶ Effects → altered mood, perception, cognition, the occurrence of elementary and complex hallucinations, as well as experiences described as insightful, transcendent, and/or mystical in nature




LSD

CLINICAL USE

- ▶ 2014 double-blind, randomized, active placebo-controlled pilot study → examined safety and efficacy of LSD-assisted psychotherapy in 12 patients with anxiety associated with life-threatening diseases
- Group comparison results supported positive trends in reduction of anxiety after two sessions of LSD-assisted psychotherapy



PSILOCYBIN

- Found in over 100 species of mushrooms
 - Characterized as a prodrug, and is dephosphorylated by hepatic first pass metabolism into the 5-HT_{2A}, 1A and 2C receptor agonist psilocin
 - Subjective effects last 4-6 hours
- 



PSILOCYBIN

CLINICAL USE

- Potential treatments for cluster headache
- Pilot studies looking at:
 - Anxiety secondary to a cancer diagnosis
 - Obsessive-compulsive disorder
 - Treatment-resistant depression
 - Smoking cessation
 - Alcoholism

SUBSTANCES

PRESCRIPTION DRUGS

- Can be very helpful drugs when used properly and when under the guidance of a qualified physician.
- Can be used as aids in surgery, to treat medical conditions and while controlling various symptoms.

Types of drugs include:

- ❖ Opioids: Codeine, Oxycodone, Morphine
- ❖ Central nervous system depressants: barbiturates, benzodiazepines
- ❖ Stimulants: dextroamphetamine, methylphenidate



SUBSTANCES

ANABOLIC STEROIDS

- Taken to improve physical performance as well as to enlarge muscles and increase strength.
- Negative effects of steroids include baldness, cysts, oily hair and skin, acne, heart attack, stroke and change in voice.
- Hostility is also a frequent side effect of anabolic steroids.

Types of drugs include:

- ❖ Anadrol
- ❖ Oxandrin
- ❖ Durabolin
- ❖ Stanozol
- ❖ Dianabol



References

1. Steyn F. Methylphenidate use and poly-substance use among undergraduate students attending a South African university. *S Afr J Psychiat.* 2016;22(1), a760.
2. Jain R, Chang C, Koto M, Geldenhuys A, Nichol R, Joubert G. Non-medical use of methylphenidate among medical students of the University of the Free State. *S Afr J Psychiat.* 2017;23, a1006
3. Bridgeman MB, Abazia D. Medicinal Cannabis: History, Pharmacology, And Implications for the Acute Care Setting. *Pharmacol Therapeut.* 2017 March; 44(3):180-188
4. Di Forti M et al. The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study. *Lancet Psychiatry.* 2019 March (online); 6:427–36
5. Perucca E. Cannabinoids in the Treatment of Epilepsy: Hard Evidence at last? *J Epilepsy Res.* 2017;7(2):61-76
6. Cohen K, Weinstein AM. Synthetic and Non-synthetic Cannabinoid Drugs and Their Adverse Effects-A Review From Public Health Prospective. *Front. Public Health.* 2018; 6:162.
7. Whiting et al. Cannabinoids for Medical Use A Systematic Review and Meta-analysis. *JAMA.* 2015;313,(24):2456-2473
8. Garcia-Romeu A, Kersgaard B, Addy PH. Clinical Applications of Hallucinogens: A Review. *Exp Clin Psychopharmacol.* 2016 August ; 24(4): 229–268



**THANK YOU
FOR
YOUR
ATTENTION!
ANY QUESTIONS?**